A Phase 1 Single Dose Open-label Reduced/staged Pharmacokinetic (PK) and Safety Study of Abiraterone Acetate (AA) in Men With Impaired Renal Function

被引：3
|
作者：
Marbury, T. [1 ]
Stonerock, R. [1 ]
Tran, N. [2 ]
Gonzalez, M. [3 ]
Jiao, J. [3 ]
Breeding, J. [2 ]
Haqq, C. M. [2 ]
Molina, A. [2 ]
Acharya, M. [3 ]
机构：
[1] Orlando Clin Res Ctr, Orlando, FL USA
[2] OrthoBiotech Oncol Res & Dev, Los Angeles, CA USA
[3] Johnson & Johnson Pharmaceut, Res & Developlment, Raritan, NJ USA
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)72008-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S502 / S502
页数：1
相关论文
共 50 条
  • [1] A Phase 1 Single-dose Open-label Pharmacokinetic (PK) Study of Abiraterone Acetate (AA) in Male Subjects With Mild or Moderate Hepatic Impairment
    Marbury, T.
    Stonerock, R.
    Acharya, M.
    Gonzalez, M.
    Jiao, J.
    Breeding, J.
    Haqq, C.
    Molina, A.
    Tran, N.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S501 - S501
  • [2] Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men
    M. Acharya
    A. Bernard
    M. Gonzalez
    J. Jiao
    R. De Vries
    N. Tran
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1583 - 1590
  • [3] Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men
    Acharya, M.
    Bernard, A.
    Gonzalez, M.
    Jiao, J.
    De Vries, R.
    Tran, N.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (06) : 1583 - 1590
  • [4] A Phase 1, Open-Label Evaluation of the Pharmacokinetics And Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Renal Function
    Greig, Gerard
    Cong, Danni
    Hurley, Niamh
    Michel, Eric
    Youssef, Nader
    TRANSPLANTATION, 2022, 106 (09) : S544 - S544
  • [5] A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function
    Ermer, James
    Corcoran, Mary
    Lasseter, Kenneth
    Marbury, Thomas
    Yan, Brian
    Martin, Patrick T.
    THERAPEUTIC DRUG MONITORING, 2016, 38 (04) : 546 - 555
  • [6] A Phase 1, Open-Label, Single-Dose Pharmacokinetic Study of Lasmiditan in Paediatric Patients with Migraine
    Tsai, Max
    Nery, Emel Serap Monkul
    Kerr, Lisa
    Khanna, Rashna
    Komori, Mika
    Dennehy, Ellen
    Wilbraham, Darren
    NEUROLOGY, 2021, 96 (15)
  • [7] A PHASE 1, OPEN-LABEL, SINGLE-DOSE PHARMACOKINETIC STUDY OF LASMIDITAN IN PAEDIATRIC PATIENTS WITH MIGRAINE
    Tsai, Max
    Nery, Emel Serap Monkul
    Kerr, Lisa
    Khanna, Rashna
    Komori, Mika
    Dennehy, Ellen B.
    Wilbraham, Darren
    CEPHALALGIA, 2020, 40 : 41 - 42
  • [8] PHARMACOKINETICS AND TOLERABILITY OF A SINGLE DOSE OF APRAGLUTIDE IN SUBJECTS WITH NORMAL AND IMPAIRED RENAL FUNCTION: A PHASE 1, OPEN-LABEL, NON-RANDOMIZED, PARALLELGROUP STUDY
    Greig, Gerard
    Hurley, Niamh
    Michel, Eric
    Youssef, Nader N.
    GASTROENTEROLOGY, 2022, 162 (07) : S654 - S654
  • [9] Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study
    Kim, Seokuee
    Lee, Jongtae
    Shin, Donghoon
    Lim, Kyoung Soo
    Kim, Yon Su
    Jang, In-Jin
    Yu, Kyung-Sang
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 1723 - 1731
  • [10] AN OPEN-LABEL, SINGLE-DOSE, PHASE 1 STUDY OF THE PHARMACOKINETICS AND SAFETY OF JZP-110 IN SUBJECTS WITH NORMAL OR IMPAIRED RENAL FUNCTION AND WITH END-STAGE RENAL DISEASE REQUIRING HEMODIALYSIS
    Zomorodi, K.
    Chen, D.
    Lee, L.
    Lasseter, K.
    Marbury, T.
    SLEEP, 2017, 40 : A382 - A382
12345